Core Viewpoint - The financial performance of Huqiang Technology (688151.SH) reveals a facade of profitability, with a significant increase in net profit driven by non-recurring gains, while the core business continues to suffer losses [1][2]. Financial Performance - In 2024, the company's net profit attributable to shareholders surged by 184.26% to 22.53 million yuan, but the adjusted net profit showed a loss of 64.96 million yuan, marking four consecutive years of losses [1]. - The profit increase was largely due to investment income contributing 51.86 million yuan, accounting for 230% of the net profit, while the operating profit loss expanded to 78.36 million yuan [1]. Core Business Challenges - The core business faces structural crises, with military product revenue increasing by 68.31% to 161 million yuan, primarily reliant on a single product, the 239 model equipment, which generated 123 million yuan in revenue [2]. - Individual protective equipment revenue plummeted by 59.24% due to declining demand for key military products [2]. - The pharmaceutical packaging segment also experienced significant declines, with revenue dropping by 89.36% in Q1 2025 [3]. Investment Projects and Liquidity Issues - Investment projects from the IPO are nearly stagnant, with the highest progress at only 32.77% and the lowest at 0.48%, raising concerns about funding efficiency [4]. - The company has faced a three-year ban from participating in military procurement due to violations, leading to a sharp decline in new military orders [4]. - Cash flow issues are evident, with a 23.12% reduction in cash reserves compared to the previous year, indicating potential liquidity crises [4].